JCRB1083 KYSE180
Cell information
Important Notice(s)Announcement of unavailability of KYSE series cell lines to oversea users outside of Japan
Cell type:general cells (View Pricing Information)
| JCRB No. | JCRB1083 | Cell Name | KYSE180 |
|---|---|---|---|
| Profile | Human well differentiated squamous cell carcinoma from esophageal cancer. | Other Name | |
| Animal | human | Strain | |
| Genus | Homo | Species | sapiens |
| Sex | M | Age | 53 |
| Identity | available | Tissue for Primary Cancer | esophagus |
| Case history | esophagus cancer, T4N1Mo Stage 3, squamous cell carcinoma (SCC) | Metastasis | No |
| Tissue Metastasized | Genetics | cyclin D1 amplification, p53 mutation | |
| Life Span | infinite | Crisis PDL | |
| Morphology | epithelial-like | Character | Xenotransplantation positive. |
| Classify | tumor | Established by | Shimada,Y. |
| Registered by | Shimada,Y. | Regulation for Distribution | |
| Comment | Year | 2003 | |
| Medium | Ham's F12 medium + RPMI1640 medium (1 to 1 mix) with 2% fetal calf serum. | Methods for Passages | Cells harvested after treatment with trypsin and EDTA. |
| Cell Number on Passage | split ratio = 1/5 | Race | Japanese |
| CO2 Conc. | 5 % | Tissue Sampling | esophagus |
| Tissue Type | Well differenciated squamous cell carcinoma. |
| Detection of virus genome fragment by Real-time PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | |||||||||
| Reference | |
|---|---|
| Pubmed id:11092977 | Nonrandom chromosomal imbalances in esophageal squamous cell carcinoma cell lines: possible involvement of the ATF3 and CENPF genes in the 1q32 amplicon. Pimkhaokham A,Shimada Y,Fukuda Y,Kurihara N,Imoto I,Yang ZQ,Imamura M,Nakamura Y,Amagasa T,Inazawa J Jpn J Cancer Res. 2000 Nov;91(11):1126-33 |
| Pubmed id:10446988 | Lymph node metastasis is associated with allelic loss on chromosome 13q12-13 in esophageal squamous cell carcinoma. Harada H,Tanaka H,Shimada Y,Shinoda M,Imamura M,Ishizaki K Cancer Res. 1999 Aug 1;59(15):3724-9 |
| Pubmed id:9699676 | Methylation of the 5' CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Tanaka H,Shimada Y,Harada H,Shinoda M,Hatooka S,Imamura M,Ishizaki K Cancer Res. 1998 Aug 1;58(15):3429-34 |
| Pubmed id:9033652 | Multiple types of aberrations in the p16 (INK4a) and the p15(INK4b) genes in 30 esophageal squamous-cell-carcinoma cell lines. Tanaka H,Shimada Y,Imamura M,Shibagaki I,Ishizaki K Int J Cancer. 1997 Feb 7;70(4):437-42 |
| Pubmed id:8575860 | Characterization of p53 gene mutations in esophageal squamous cell carcinoma cell lines: increased frequency and different spectrum of mutations from primary tumors. Tanaka H,Shibagaki I,Shimada Y,Wagata T,Imamura M,Ishizaki K Int J Cancer. 1996 Jan 26;65(3):372-6 |
| Pubmed id:9816044 | p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. Shibagaki I,Tanaka H,Shimada Y,Wagata T,Ikenaga M,Imamura M,Ishizaki K Clin Cancer Res. 1995 Jul;1(7):769-73 |
| Pubmed id:7913084 | Analysis of gene amplification and overexpression in human esophageal-carcinoma cell lines. Kanda Y,Nishiyama Y,Shimada Y,Imamura M,Nomura H,Hiai H,Fukumoto M Int J Cancer. 1994 Jul 15;58(2):291-7 |
| Pubmed id:8518899 | Prognostic significance of cell culture in carcinoma of the oesophagus. Shimada Y,Imamura M Br J Surg. 1993 May;80(5):605-7 |
| Pubmed id:1728357 | Characterization of 21 newly established esophageal cancer cell lines. Shimada Y,Imamura M,Wagata T,Yamaguchi N,Tobe T Cancer. 1992 Jan 15;69(2):277-84 |
| Images |
|---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
LOT Information
Viability/Growth rate/Cell number are represented as actual values measured at lot presentation in JCRB, but are not guaranteed values. Additionally, the doubling time is a rough value measured during passages.| Cell No. | JCRB1083 | Cell Name | KYSE180 |
|---|---|---|---|
| LOT No. | 07252008 | Lot Specification | distribution |
| Medium | RPMI1640(GIBCO) and Ham's F12 medium(GIBCO)(1/1) with 2% heat inactivated fetal bovine serum(Hyclone GRD0051) | Temperature | 37 C |
| Cell Density at Seeding | 1.9x10^4 cells/sq.cm | Methods for Passages | Cells were harvested after treatment with 0.25% trypsin and 0.02% EDTA. |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 2.2x10^6 |
| Viability at cell freezing (%) | 98.9 | Antibiotics Used | free (this lot was pretreated with plasmocin) |
| Passage Number | p715 | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:8,11 D13S317:9,12 D7S820:9,12 D16S539:9,10 VWA:16,17 TH01:7 AM:X TPOX:11 CSF1PO:12,13 |
| Adhesion | Yes | Exoteric Gene | NT |
| Medium for Freezing | Cell Banker BLC-1(Nihon Zenyaku Industries) | CO2 Conc. | 5 % |
| Viability immediately after thawing (%) | Additional information |
| Images |
|---|
![]() ![]() ![]() |
| Cell No. | JCRB1083 | Cell Name | KYSE180 |
|---|---|---|---|
| LOT No. | 08012008 | Lot Specification | distribution |
| Medium | RPMI1640(GIBCO) and Ham's F12 medium(GIBCO)(1/1) with 2% heat inactivated fetal bovine serum(Hyclone GRD0051) | Temperature | 37 C |
| Cell Density at Seeding | 1.9x10^4 cells/sq.cm | Methods for Passages | Cells were harvested after treatment with 0.25% trypsin and 0.02% EDTA. |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 4.0x10^6 |
| Viability at cell freezing (%) | 99.0 | Antibiotics Used | free (this lot was pretreated with BM cyclin 1and |
| Passage Number | p716 | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:8,11 D13S317:9,12 D7S820:9,12 D16S539:9,10 VWA:16,17 TH01:7 AM:X TPOX:11 CSF1PO:12,13 |
| Adhesion | Yes | Exoteric Gene | NT |
| Medium for Freezing | Cell Banker BLC-1(Nihon Zenyaku Industries) | CO2 Conc. | 5 % |
| Viability immediately after thawing (%) | Additional information |
| Images |
|---|
![]() ![]() ![]() |
| Cell No. | JCRB1083 | Cell Name | KYSE180 |
|---|---|---|---|
| LOT No. | 10222004 | Lot Specification | distribution |
| Medium | 1 to 1 mix of Ham's F12 and RPMI1640 medium containing 2% fetal calf serum. | Temperature | 37 C |
| Cell Density at Seeding | 4.0 x 10^4 cells / sq. cm | Methods for Passages | Cells were harvested after treatment with 0.25% trypsin about 5 min. Subculture once a week and medium change every 2-4 days. |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 3.8x10^6 |
| Viability at cell freezing (%) | 96 | Antibiotics Used | free |
| Passage Number | P715 | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | |
| Adhesion | Yes | Exoteric Gene | NT |
| Medium for Freezing | Culture medium containing 5% DMSO at final concentration. | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | Additional information |
| Images |
|---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
























